Katharina Kranzer1, Nathan Ford. 1. Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK. katharina.kranzer@lshtm.ac.uk
Abstract
OBJECTIVE: To characterize the frequency, reasons, risk factors, and consequences of unstructured anti-retroviral treatment interruptions. METHOD: Systematic review. RESULTS: Seventy studies were included. The median proportion of patients interrupting treatment was 23% for a median duration of 150 days. The most frequently reported reasons for interruptions were drug toxicity, adverse events, and side-effects; studies from developing countries additionally cited treatment costs and pharmacy stock-outs as concerns. Younger age and injecting drug use was a frequently reported risk factor. Other risk factors included CD4 count, socioeconomic variables, and pharmacy stock outs. Treatment interruptions increased the risk of death, opportunistic infections, virologic failure, resistance development, and poor immunological recovery. Proposed interventions to minimize interruptions included counseling, mental health services, services for women, men, and ethnic minorities. One intervention study found that the use of short message service reminders decrease the prevalence of treatment interruption from 19% to 10%. Finally, several studies from Africa stressed the importance of reliable and free access to medication. CONCLUSION: Treatment interruptions are common and contribute to worsening patient outcomes. HIV/AIDS programmes should consider assessing their causes and frequency as part of routine monitoring. Future research should focus on evaluating interventions to address the most frequently reported reasons for interruptions.
OBJECTIVE: To characterize the frequency, reasons, risk factors, and consequences of unstructured anti-retroviral treatment interruptions. METHOD: Systematic review. RESULTS: Seventy studies were included. The median proportion of patients interrupting treatment was 23% for a median duration of 150 days. The most frequently reported reasons for interruptions were drug toxicity, adverse events, and side-effects; studies from developing countries additionally cited treatment costs and pharmacy stock-outs as concerns. Younger age and injecting drug use was a frequently reported risk factor. Other risk factors included CD4 count, socioeconomic variables, and pharmacy stock outs. Treatment interruptions increased the risk of death, opportunistic infections, virologic failure, resistance development, and poor immunological recovery. Proposed interventions to minimize interruptions included counseling, mental health services, services for women, men, and ethnic minorities. One intervention study found that the use of short message service reminders decrease the prevalence of treatment interruption from 19% to 10%. Finally, several studies from Africa stressed the importance of reliable and free access to medication. CONCLUSION: Treatment interruptions are common and contribute to worsening patient outcomes. HIV/AIDS programmes should consider assessing their causes and frequency as part of routine monitoring. Future research should focus on evaluating interventions to address the most frequently reported reasons for interruptions.
Authors: Leigh F Johnson; Janne Estill; Olivia Keiser; Morna Cornell; Haroon Moolla; Michael Schomaker; Anna Grimsrud; Mary-Ann Davies; Andrew Boulle Journal: Am J Epidemiol Date: 2014-11-15 Impact factor: 4.897
Authors: Aimalohi A Ahonkhai; Juliet Adeola; Bolanle Banigbe; Ifeyinwa Onwuatuelo; Abdulkabir B Adegoke; Ingrid V Bassett; Elena Losina; Kenneth A Freedberg; Prosper Okonkwo; Susan Regan Journal: J Int Assoc Provid AIDS Care Date: 2016-10-10
Authors: Robert A Bonacci; Katherine Frasca; Lyles Swift; Daohang Sha; Warren B Bilker; Laura Bamford; Baligh R Yehia; Robert Gross Journal: AIDS Behav Date: 2016-05
Authors: Loveleen Bansi-Matharu; Gabriela Rodriguez Loria; Stephen R Cole; Henry Mugerwa; Isabel Vecino; Jens Lundgren; Piotr Pulik; Colette Smith; Andrew N Phillips Journal: AIDS Date: 2019-07-01 Impact factor: 4.177
Authors: Awachana Jiamsakul; Stephen J Kerr; Oon Tek Ng; Man Po Lee; Romanee Chaiwarith; Evy Yunihastuti; Kinh Van Nguyen; Thuy Thanh Pham; Sasisopin Kiertiburanakul; Rossana Ditangco; Vonthanak Saphonn; Benedict L H Sim; Tuti Parwati Merati; Wingwai Wong; Pacharee Kantipong; Fujie Zhang; Jun Yong Choi; Sanjay Pujari; Adeeba Kamarulzaman; Shinichi Oka; Mahiran Mustafa; Winai Ratanasuwan; Boondarika Petersen; Matthew Law; Nagalingeswaran Kumarasamy Journal: Trop Med Int Health Date: 2016-03-29 Impact factor: 2.622
Authors: H Samji; T E Taha; D Moore; A N Burchell; A Cescon; C Cooper; J M Raboud; M B Klein; M R Loutfy; N Machouf; C M Tsoukas; J S G Montaner; R S Hogg Journal: HIV Med Date: 2014-09-01 Impact factor: 3.180